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The “estrogen paradox” in pulmonary arterial hypertension (PAH) refers to observations that while there is a higher incidence of
idiopathic PAH in women, rodent models of PAH showmale dominance and estrogens are protective. To explain these differences,
we previously proposed the neuroendocrine-STAT5-BCL6 hypothesis anchored in the sex-biased and species-specific patterns of
growth hormone (GH) secretion by the pituitary, the targeting of the hypothalamus by estrogens to feminize GH secretion
patterns, and the role of the transcription factors STAT5a/b and BCL6 as downstream mediators of this patterned GH-driven
sex bias. As a test of this hypothesis, we previously reported that vascular smooth muscle cell- (SMC-) specific deletion of the
STAT5a/b locus abrogated the male-dominant sex bias in the chronic hypoxia model of PAH in mice. In the present study, we
confirmed reduced BCL6 expression in pulmonary arterial (PA) segments in both male and female SMC:STAT5a/b−/− mice. In
order to test the proposed contribution of BCL6 to sex bias in PAH, we developed mice with SMC-specific deletion of BCL6+/−
by crossing SM22α-Cre mice with BCL6-floxed mice and investigated sex bias in these mutant mice in the chronic hypoxia
model of PAH. We observed that the male-bias observed in wild-type- (wt-) SM22α-Cre-positive mice was abrogated in the
SMC:BCL6+/− knockouts—both males and females showed equivalent enhancement of indices of PAH. The new data
confirm BCL6 as a contributor to the sex-bias phenotype observed in hypoxic PAH in mice and support the neuroendocrine-
STAT5-BCL6 hypothesis of sex bias in this experimental model of vascular disease.
1. Introduction
Idiopathic pulmonary arterial hypertension (IPAH) is a
disease with high morbidity and mortality with limited
therapeutic options [1–5]. The histologic vascular lesions in
the lungs are characterized by segmental pulmonary arterial
remodeling and proliferation of the vascular smooth muscle
andendothelial cells to formplexiformand “onion-skin”oblit-
erative lesions which occlude the vascular lumen and cause
increased mean pulmonary artery pressure (>25mm Hg)
and right ventricular hypertrophy [1–4]. Diverse inherited
autosomal-dominant mutations in the BMPR2 gene underlie
a significant subset of IPAH cases, but with low penetrance
[1–4, 6–8]. There is a distinct sexual dimorphism in IPAH
in that this disease affects postpubertal women (median age
at diagnosis: in the third decade) with 2–4-fold greater inci-
dence than men (median age at diagnosis: in the fourth
decade) [1–11]. However, disease progression is more rapid
in men than in women [9]. The mechanisms that determine
this sexual dimorphism in humans are incompletely under-
stood. Puzzlingly, several studies have pointed to a direct
protective effect of estrogens on development of an equivalent
pulmonary arterial hypertension (PAH) disease process in
experimental animals (such as in mice and rats exposed to
chronic hypoxia or in rats exposed to monocrotaline pyrrole)
([9–21], and citations therein). Thus, in these experimental
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models in mice and rats it is the males that preferentially
developmore pronounced disease, while exogenously admin-
istered estrogens have proven to be protective.
In attempting to understand the mechanistic basis of this
species-dependent sex-bias paradox (higher incidence of
IPAH in women, but greater susceptibility to PAH in male
mice and rats, with exogenous estrogens having a protective
effect) [9–18], we discovered that smooth muscle cells
(SMCs) in obliterative IPAH lesions in humans had a marked
reduction in levels of the sex-responsive transcription factors
STAT5a and STAT5b (collectively either “STAT5a/b” or
“STAT5”), their activated Tyr-phosphorylated entities
(PY-STAT5), and a downstream sex-responsive target of
STAT5—the “broad-spectrum” transcriptional repressor
B-cell lymphoma 6 protein (BCL6) (Figure 1) [19–21].
This discovery focused our attention on the possibility that
the resolution of the species-specific sex-bias paradox in
PAH between human females (greater susceptibility to
PAH than males) and rodent females (lesser susceptibility
to PAH than males) might reside in the well-known differ-
ences in the patterns of sex-biased secretion of growth
hormone (GH)—a well-characterized upstream activator of
STAT5a/b [19–21]. Women have a high baseline level of
GH with small frequent peaks (a pattern referred to as “more
continuous”), while men have a low baseline with few but
high level peaks of GH (a pattern referred to as “pulsatile”)
([20–29], and citations therein) (Figure 1). Thus, circulating
GH levels in men comprise 2–4 peaks per day with very
low interpulse levels, while in women there is a higher fre-
quency of pulses (>7 peaks/day) with significantly elevated
interpulse levels (Figure 1) ([22–25]; reviewed in [20, 21]).
Even when assayed at a single time-point in humans (in the
morning after fasting), the median value of serum GH levels
was 80–120-fold higher in young adult women than in young
adult men [25]. This is a higher sexual dimorphism ratio than
that for estradiol-17β (E2) (ratio: 2.2-fold female bias) or tes-
tosterone (ratio: 14-fold male bias) observed in the same sera
[25]. Mice and rats also show similar quantitative differences
in the respective male versus female patterns of circulating
GH ([26–29], reviewed in [21]) (Figure 1). Male rodents
show discrete GH pulses approximately every 3–5hr with lit-
tle or no circulating GH detectable during the interpulse
interval, while in female rats, the pulses are more frequent,
the pulse heights are lower, and the interpulse levels are
relatively low but nonzero [26–29]. Overall, when compared
to GH levels at peak pulse height, female humans have a
relatively high interpulse level, while female rodents have a
low interpulse level ([22–29]; reviewed in [20, 21]). We have
pointed to this difference in relative interpulse levels as a key
difference between women and female rodents that might
underlie the estrogen paradox [19–21]. It is noteworthy that
the pulsatility in GH levels is largely unconnected to the
day-night circadian rhythms or the pulsatility of the cardiac
cycle [20–29].
There is extensive neuroendocrinology literature show-
ing that these patterns are derived from the patterned secre-
tion of GH by the anterior pituitary in response to
hypothalamic input via neuronal GHRH secretion which is
in turn affected by estrogens (e.g., estradiol-17β (E2)) at the
level of the arcuate nucleus (and other sites) in the ventrome-
dial hypothalamus [30–42]. In terms of downstream mecha-
nisms, there is also extensive literature mechanistically
linking these GH pulsatility patterns to patterned activation
of STAT5a/b (frequency and level of activation by Tyr phos-
phorylation) with resulting patterned activation of the tran-
scriptional repressor BCL6 and hundreds of downstream
genes (Figure 1) [43–51]. Remarkably, it has been established
beginning in the late 1970s that the feminizing effect of exog-
enously administered estrogens on liver gene expression
obligatorily required the pituitary in that hypophysectomy
blocked this sex-bias effect of estrogens (Figure 1) [30–42].
Thus, although there is considerable research on the interac-
tions between the estrogens, the estrogen receptors, and
STAT5 and other transcription factors at the level of distal
target tissues [47], there is also clear evidence that a major
mechanism of the sex-bias effects of exogenously adminis-
tered estrogens begins with the interaction of sex hormones
with the hypothalamus and changes in the subsequent cas-
cade of patterned activation of the GH-STAT5 axis in distal
tissues (Figure 1) [30–51]. Thus, especially in light of the
“estrogen paradox” in PAH [6, 9], we proposed the
neuroendocrine-STAT5 hypothesis of sex bias in this disease
to account for the difference between humans and rodents
(Figure 1) [19–21].
Experimentally, after observing that SMCs in obstructive
pulmonary arterial lesions in IPAH in both female and male
patients showed reduced STAT5a/b and reduced PY-STAT5
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Figure 1: Schematic of the pathway involving the contributions of neuroendocrine-STAT5-BCL6mechanisms of sex bias in PAH. Patterns of
circulating GH in males typically consist of a low baseline level with few (2–4) but high peak levels (a pattern customarily referred to as
“pulsatile”) [22–29]. Females have a higher baseline level of GH with small frequent peaks (≥7 per day) (a pattern referred to as “more
continuous”) [22–29]. E2, estradiol-17β; M,male; F, female; downward short arrows indicate reduction; upward short arrow indicates increase.
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the chronic hypoxia model in mice. In this model, wild-type
(wt) mice show a male-dominant phenotype. We developed
tissue-specific knockout mice with heterozygous or homozy-
gous deletion of STAT5a/b in vascular smooth muscle cells
(SMCs) and investigated the influence of these deletions on
the male dominance in this model of PAH [19]. We observed
that SMC-specific heterozygous or homozygous deletion of
STAT5a/b abrogated the male-dominant sex bias in that both
female and male mice developed PAH (increased right ven-
tricular systolic pressure (RVSP), hypertrophy of pulmonary
arterial vessel wall, and right ventricular hypertrophy) to a
similar extent [19–21].
We then focused on experimentally testing a downstream
element in the GH-STAT5 hypothesis (Figure 1). It is well
established that the transcriptional repressor BCL6 is one of
the major transcription factors downstream of STAT5 in
the sex-biased regulation of expression of hundreds of liver
genes [50, 51]. We have previously reported that BCL6 was
also reduced in SMCs in obliterative pulmonary arterial
lesions in both women and men with IPAH concomitant
with the reduction in STAT5a/b and PY-STAT5 levels [21].
It is also already known that whole-body homozygous dele-
tion of BCL6−/− in the mouse led to extensive pulmonary
edema and pulmonary parenchymal and vascular inflamma-
tion [52]. Thus, from the point of view of downstream
mechanisms in the STAT5 hypothesis, we investigated (a)
whether SMC-specific deletion of STAT5a/b in the mouse
had an effect on expression of BCL6 in SMCs in pulmonary
arterial tunica media and (b) whether SMC-specific deletion
of BCL6 in the mouse had an effect on chronic hypoxia-
induced PAH and its male-dominant sex-bias phenotype
(Figure 1). The new data reported here represent a successful
test of the BCL6 element in the GH-STAT5-BCL6 hypothesis
of sex bias in PAH [19–21].
2. Materials and Methods
2.1. Derivation of Mice with Smooth Muscle Cell- (SMC-)
Specific Heterozygous and Homozygous Deletions of
STAT5a/b or BCL6. Mouse breeding, care, and use of
animals for these studies was approved by the Institutional
Animal Care and Use Committee (IACUC) of the New York
Medical College. A mouse line with SMC-specific homozy-
gous deletion of the STAT5a/b locus had been previously
produced by mating STAT5a/bfl/fl mice carrying loxP inserts
bracketing the entire STAT5a/b locus in C57BL/6:129J mice
provided by Dr. Lothar Hennighausen (National Institutes
of Health, Bethesda, MD) with SM22-Cre+/+ mice (express-
ing Cre recombinase under the control of the mouse transge-
lin (smooth muscle protein 22α) promoter) purchased from
The Jackson Laboratories, Bar Harbor, ME (stock number:
004746 Tg (Tagln-cre)1Her/J in C57BL/6:129SJL back-
ground) [19]. PCR analyses of the tail DNA using appropri-
ate primers were used to confirm the genotype of the
Cre-positive mice with respect to the presence of STAT5a/b
wt or fl or Cre alleles [19]. All mice in the present studies des-
ignated “Wt” were Cre-positive littermates not carrying any
STAT5a/b-floxed alleles [19]. The selective reduction in
STAT5 expression in the tunica media of pulmonary arterial
segments in the Cre-positive heterozygous STAT5a/b wt/fl
(designated “+/−”) or homozygous fl/fl (designated “−/−”)
mice was verified in immunofluorescence and immunohisto-
chemistry assays for STAT5 [19]. Smooth muscle α-actin-
(SMA-) positive aortic smooth muscle cells (SMCs) derived
from the homozygous knockouts showed a marked loss of
STAT5a/b by Western blotting [19]. Lung tissues from Wt
and SMC:STAT5a/b−/− mice used in the immunofluores-
cence analyses for BCL6 were from experiments previously
reported in Figure 4 in [19].
Mouse lines (in C57BL/6 background) with SMC-specific
heterozygous and homozygous deletions of BCL6 were gen-
erated in the same manner described above by cross-mating
the BCL6fl/fl (B6.129S (FVB)-Bcl6tm1.1Dent/J; stock number:
023727 Bcl6fl) and SM22α-Cre+/+ mice (stock number:
004746) purchased from The Jackson Laboratories, Bar
Harbor, ME, and confirmed by PCR analyses of tail DNA
using appropriate primers designated by the supplier. All
mice in the BCL6 studies designated “Wt” were Cre-positive
littermates not carrying any BCL6-floxed alleles. Reduced
expression of BCL6 in the tunica media and SMCs of pulmo-
nary artery segments of the mutant mice was confirmed by
immunofluorescence analyses (Figure 2). These mutant mice,
including the SMC-specific STAT5a/b−/− and SMC-specific
BCL6+/− and −/− knockouts have no fertility or growth
issues. In the present study, we used the more abundantly
available male and female heterozygous SMC-specific BCL6
+/− for the chronic hypoxia treatment.
2.2. Exposure to Hypoxia. Groups ofWt, or mutant male and
female mice at approximately 8 weeks of age were used in the
respective chronic hypoxia experiments (n = 4 – 7 mice per
group per variable; average group size n = 5mice) [19]. Mice
were exposed to hypobaric hypoxia (0.5 atmospheres in
room air equivalent to 10% v/v oxygen) for approximately 4
weeks; normoxia controls were left in ordinary room air [19].
2.3. Assessment of PAH and Lung Vascular Remodeling after
Chronic Hypoxia. This was carried out as previously
described in [19]. Briefly, mice were anaesthetized using the
ketamine/xylazine cocktail (100mg/kg ketamine, 10mg/kg
xylazine, intraperitoneally). A Millar catheter was used for
the in vivomeasurement of right ventricular systolic pressure
(RVSP) via external jugular vein catheterization (PVR-1030;
Millar Instruments Inc., Houston, TX). The animals were
then euthanized and the heart, aorta, and left lung removed
and formalin fixed (the right lung was snap-frozen in
liquid N2). The heart was dissected to obtain the ratio of
right ventricle weight to that of the left ventricle plus septum
(RV/LV+S) as a measure of right ventricular hypertrophy
(RVH). The left lung was used for paraffin block embedding
and histology (hematoxylin & eosin, Van Gieson’s elastin
and Masson’s Trichrome stains, and immunofluorescence
for smooth muscle actin (SMA)). The extent of vascular
remodeling in pulmonary arteries with an outer diame-
ter< 80μmwas quantitated in terms of medial wall thickness
expressed as 2x wall thickness in % of average vessel outer
diameter measured in two axes perpendicular to each other
[19]. Muscularization of pulmonary vessels in lung sections
3International Journal of Endocrinology
was evaluated as indicated in Section 2.4. All histological
quantitation was carried out in a blinded fashion.
2.4. Immunofluorescence Analyses of Lung Sections. Serial
sections (5μm) of formalin-fixed, paraffin-embedded lung
tissue were evaluated for BCL6 and smooth muscle α-actin
(SMA) immunofluorescence as described earlier [19] using
rabbit pAb for BCL6 or mouse mAb for SMA, and respective
donkey AlexaFluor 594-tagged pAb (in red) as the secondary
antibody. Imaging was carried out using a Zeiss AxioImager
M2 motorized microscopy system equipped with a high-
resolution RGB HRc AxioCam camera and AxioVision
4.8.1 software in a 1388× 1040 pixel high-speed color capture
mode. All data within each experiment were collected at
identical imaging settings. Fluorescence intensity was quanti-
tated using the NIH Image J software [19]. Muscularization
of pulmonary vessels< 80μm in diameter was evaluated by
immunofluorescence of SMA in lung sections and expressed
as the mean number of SMA-positive vessels per 10x
objective field.
2.5. Antibodies. Rabbit pAb to BCL6 (N-3) (Cat. number:
sc-858) was purchased from Santa Cruz Inc., Santa Cruz,
CA. Mouse mAb to SMA (Cat. number: A5228) was from
Sigma-Aldrich Inc., St. Louis, MO. Alexa-Flour-tagged
donkey secondary antibodies were from Life Technologies,
Grand Island, NY.
2.6. Statistical Evaluations. These were performed using the
two-tailed Student t-test (as in Figure 2) and single-factor
ANOVA methods (NCSS version 8, 2012). Multiple group
comparisons were carried out using ANOVA (Tukey-
Kramer, Newman-Keuls, and Tukey-Kramer tests).





















































































Figure 2: Reduced BCL6 expression in the tunica media/SMCs in sections of the main PA arteries in mice with SMC-specific heterozygous or
homozygous deletion of the BCL6 locus. Sections of the main PA arteries from Wt and respective mutant mice were evaluated for BCL6
expression by quantitative immunofluorescence. (a) Autofluorescence (in green) of the elastic laminae was used to identify the tunica
media. (c) SMCs in the tunica media were immunostained for smooth muscle α actin (SMA). Arrows in the Wt sections draw attention to
areas of normal BCL6 immunofluorescence and those in the mutant sections to areas with reduced BCL6 expression. (b, d) Summary of
BCL6 immunofluorescence intensity in multiple areas of sections such as in (a) and (c) in the Wt and respective mutant mice. ∗P < 0 05
by Student’s t-test.
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3. Results
3.1. SMC-Specific STAT5a−/− Deletion Leads to Reduced
BCL6 Expression in Pulmonary Arterial Tunica Media. We
used quantitative immunofluorescence methods to investi-
gate whether BCL6 might be downstream of STAT5 in
SMCs in the pulmonary arterial vasculature. Groups of male
and female Wt and STAT5−/− mice were exposed to hyp-
oxia (10% hypobaric oxygen) for 4 weeks or kept under nor-
moxic conditions, and the development of PAH was first
evaluated as previously reported (RVSP, ratio of RV/LV+S
weights, increased muscularization of vessels, and increased
arterial wall thickness) [19]. From the data previously
reported, we observed in this experiment that STAT5−/−
deletion abrogated the male-dominant phenotype of PAH
in this model—the knockout female and male mice devel-
oped equivalently high levels of PAH [19]. There was little
change in heart rate or systemic blood pressure in these mice
[19]. Subsequently, representative formalin-fixed paraffin-
block sections of lungs were quantitatively evaluated for
expression of BCL6 in the pulmonary arterial (PA) walls as
a ratio to that in bronchial epithelium in different groups
(Figure 3). The immunofluorescence data in Figure 3(a)
(arrows) and the quantitation summarized in Figure 3(b)
show a reduction in BCL6 immunofluorescence in PA
segments in male and female STAT5−/− mice under both
normoxic and hypoxic conditions. These data were consistent
with the positioning of BCL6 downstream of STAT5 in
mouse pulmonary arterial SMCs in a manner similar to



































































Figure 3: Reduced BCL6 expression in pulmonary arterial (PA) segments in SMC:STAT5a/b−/− male and female mice in normoxia and
hypoxia. (a) Representative immunofluorescence images for expression of BCL6 in PA segments in lungs of Wt and SMC:STAT5a/b−/−
male and female mice (arrows) kept for 4 weeks in normoxia or hypoxia. The lung sections used for this experiment derive from the
mouse experiment reported in Figure 4 in [19]. Scale bar = 20μm. (b) Quantitation of BCL6 expression in PA segments as illustrated in
(a) expressed as a ratio of fluorescence in PA segments compared to that in the adjacent bronchial epithelium in the same section. n= the
number of arterial segments quantitated per group; ∗P < 0 05 by ANOVA.
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(Figure 1) [49–51]. These data are consistent with the infer-
ence that STAT5a/b are positive transcription factors for
expression of BCL6 in pulmonary arterial tissue (Figure 1),
an inference previously validated extensively in the liver and
isolated hepatocytes by Waxman and colleagues [47–51].
3.2. Development of SMC-Specific BCL6+/− and BCL6−/−
Knockout Mice. We generated lines of C57Bl6 mice with
heterozygous or homozygous deletions of the BCL6 locus in
vascular SMCs in crosses between BCL6fl/fl and transgelin
(SM22α)-Cre+/+ parents using methods previously described
for the generation of SMC-specific STAT5+/− and −/− mice
[19]. In addition to molecular characterization (using PCR
methods summarized in [19]; data not shown), quantitative
immunofluorescence methods were used to verify the
reduced expression of BCL6 in the pulmonary arterial tunica
media and SMCs in mice with SMC:BCL6+/− deletion
(Figures 2(a) and 2(b)) and SMC:BCL6−/− deletion
(Figures 2(c) and 2(d)). SMC-specific heterozygous and
homozygous deletion of BCL6 reduced the levels of expres-
sion of BCL6 in the tunica media/SMCs in PA segments of
the respective knockout mice but not in the endothelium
(Figures 2(a) and 2(c)).
3.3. Abrogation of the Male-Dominant Sex Bias in Hypoxic
PAH in BCL6+/− Mice. We were able to generate sufficient
SMC:BCL6+/− mice and Cre-positive “wt” littermates of
both sexes to provide groups of 4–7 mice for evaluation
indices of PAH per variable as indicated in Figure 4. (Only
a limited number of SMC:BCL6−/− mice were generated in
this project; these provided confirmatory preliminary data;
see below.) Male and female Wt and SMC:BCL6+/− mice
(n = 4–7 per group) were exposed to 10% hypobaric oxygen
or normoxia for 4 weeks and evaluated for development of
PAH. The data in Figure 4(a) show the mean RVSP in these
groups in normoxia and in response to chronic hypoxia.
There is a clear male-dominant phenotype in the increase
in mean RVSP in Wt mice in response to hypoxia. In con-
trast, this sex bias was absent in BCL6+/− mice; both males
and females showed increased RVSP in response to hypoxia.
Figure 4(b) shows the RVSP data for individual mice. The
data show that even under normoxia, one male and three
female BCL6+/− mice had RVSP levels> 25mm Hg. More-
over, all male and female BCL6+/− hypoxic mice had mark-
edly elevated RVSPs (Figure 4(b)). Overall, the data in
Figure 4 provide evidence showing that (a) even an heterozy-
gous deletion of BCL6 in vascular SMCs led to an enhance-
ment of the chronic hypoxia-induced increase in RVSP
irrespective of sex, and (b) that there was a detectable
increase in RVSP even in male and female knockout mice
under normoxic conditions (Figure 4(a)). In preliminary





































Figure 4: Abrogation of the male sex bias in chronic hypoxia-induced PAH in SMC:BCL6+/− mice: right ventricular systolic pressures
(RVSP). Groups of male and female Wt and SMC:BCL6+/− knockout mice (n = 4–7 mice per group as indicated) were subjected to
hypobaric hypoxia (10% v/v oxygen) or kept in room air for 4 weeks. At the end of the experiment, Millar catheterization was used to
measure the RVSP (Figure 4 and [19]), the PA wall thickness (see Figure 5), muscularization of PA vessels in lung sections (Figure 6(a)),
and right ventricular hypertrophy (the ratio of RV/LV+ S wet weights) (Figure 6(b)). (a) Mean RVSP is shown in each group (mean± SE).
(b) The RVSP for each individual mouse is shown.∗P < 0 05 by ANOVA; NS, not significant.
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also showed an equivalent enhancement of RVSP after
chronic hypoxia (data not shown).
Figures 5(a) and 5(b) summarize pulmonary arterial wall
thickness data from the experiment in Figure 4. Again, the
male-dominant sex bias in response to chronic hypoxia in
terms of increased wall thickness in Wt mice was abrogated
in BCL6+/− mice (Figures 5(a) and 5(b)). Moreover, there
appeared to be an increase in wall thickness in both male
and female knockout mice even under normoxic conditions
(Figure 5(b)). Figure 6(a) summarizes data pertaining to
increased muscularization of pulmonary vessels in lung
sections from hypoxic mice, while Figure 6(b) summarizes
development of right ventricular hypertrophy measured in
terms of the Fulton index (ratio of RV/LV+S weights). As
expected, a male-dominant phenotype was observed in Wt
hypoxic mice, but there was little sex bias in hypoxic
SMC:BCL6+/− mice in terms of these indices of PAH
(Figures 6(a) and 6(b)).
Taken together the data in Figures 4–6 provide evidence
for a contribution of BCL6 in the sex-bias phenotype of
PAH observed in chronically hypoxic mice. Even heterozy-
gous deletion of BCL6 in vascular SMCs rendered female
mice equally susceptible to the development of hypoxic



























































Figure 5: Abrogation of the male-sex bias in chronic hypoxia-induced PAH in SMC:BCL6+/− mice: hypertrophy of PA arterial wall
thickness. Lungs derived from the experiment in Figure 4 were processed for histological sections and stained for elastin using Van
Giesson’s reagent. Wall thickness of PA segments with a diameter< 80 μm was quantitated in terms of the ratio of 2x wall thickness/outer
diameter as reported earlier [14]. (a) Representative histologic sections are illustrated. (b) The numerical data (mean± SE) are
summarized. Scale bar = 20 μm. ∗P < 0 05 by ANOVA; NS, not significant.
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previous finding that heterozygous SMC-specific deletion of
STAT5a/b was sufficient to abrogate the male-specific sex
bias in the hypoxic mouse model [19].
4. Discussion
This study represents a specific test of the downstream BCL6
element in the GH-STAT5-BCL6 hypothesis of sex bias in
PAH (Figure 1) [19–21]. In a previous study, we provided
experimental support for this hypothesis by showing that
vascular SMC-specific deletion of the STAT5a/b locus in
mice abrogated the male-dominant sex bias observed in the
chronic hypoxic PAH model [19]. In the present study, we
have tested the next downstream element—BCL6—in this
hypothesis (Figure 1). Consistent with its placement down-
stream of STAT5 [49–51], we observed reduced BCL6 levels
in the tunica media/SMCs in pulmonary arterial segments
in male and female mice with homozygous SMC-specific
deletion of STAT5a/b (Figure 3). We then investigated
whether SMC-specific deletion of BCL6 (+/−) affected the
observed sex bias in the chronic hypoxia model. We
observed the abrogation of the male-dominance in the devel-
opment of PAH in the knockout mice. Both male and female
SMC:BCL6+/− knockout mice responded equally to chronic
hypoxia in terms of PAH development (Figures 4–6). Thus,
these data place BCL6 in the STAT5-anchored sex-bias path-
way in this experimental model and represent a successful
critical test of the GH-STAT5-BCL6 hypothesis of sex bias
in a vascular disease.
The novelty of the present study resides in the realiza-
tion that insights accumulated over the last 30–40 years in
a sister field (sex-biased expression of liver genes) and the
neuroendocrine mechanisms by which exogenously adminis-
tered estrogens influences these (Figure 1) [30–51] is largely
missing from the vascular biology field, and especially the
pulmonary hypertension field [1–18]. The critical insight
from the liver field from the 1970s, was that the effects of
exogenously administered estrogens on feminization of sex-
biased gene expression in the liver in rodent models were
absolutely dependent on the pituitary—hypophysectomy
blocked the feminization (Figure 1) [30–42]. The target of
injected estrogens included the arcuate nucleus, and addi-
tional nuclei, in the hypothalamus (Figure 1) [30–42]. In
terms of vascular biology, that hypophysectomy in the male
rat markedly impaired arterial remodeling after aortic bal-
loon injury in terms of reduced vascular SMC proliferation
and myointima formation, was reported in 1978 [53], and
confirmed [54], but this research was not pursued further.
Moreover, that ghrelin, a GH secretagogue and vasodilator
(which antagonizes endothelin-1), inhibited hypoxia- or
monocrotaline-induced PA remodeling in male rats is now
known [55–57], yet neuroendocrine mechanisms have
received little attention in the sex bias observed in vascular
disease. Thus far, most research on sex bias in the vascular
field has focused on the direct effects of sex hormones on
vascular tissues [6, 7, 9–18].
As elucidated in detail by Waxman et al. and other inves-
tigators in the last two-three decades, this neuroendocrine
mechanism of sex bias, operating through an axis consisting
of the arcuate nucleus, growth hormone releasing hormone
(GHRH), growth hormone (GH), and signal transducer and
activator of transcription 5 (STAT5), accounts for sex-
biased expression of ~500–1000 genes in the liver, and also




























































Figure 6: Abrogation of the male sex bias in chronic hypoxia-induced PAH in SMC:BCL6+/−mice: muscularization of pulmonary vessels in
lung sections and right ventricular hypertrophy (Fulton’s index). (a) Lung sections from mice shown in Figure 4 were immunostained for
SMA and the average number of muscularized vessels per 10x field were enumerated for each (mean± SE). (b) Hearts derived from the
experiment in Figure 4 were fixed in 4% formalin, rinsed in PBS and dissected into the right ventricle (RV) and the left ventricle plus
septum (LV+ S) portions. The ratio of the wet weights of RV/LV+ S (mean± SE) illustrates the extent of right ventricular hypertrophy
irrespective of the total weight of the individual heart. ∗P < 0 05 by ANOVA; NS, not significant.
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Downstream of STAT5 is a major cascade of sex-specific
regulated gene expression of 500–1000 genes (including
other transcription repressors such as BCL6; transcription
activators such as Cux2, HNF4α, HNF6, and P450 CYP
enzyme species; cell-cycle regulators; cytokines; growth fac-
tors; and immune mediators) [43–51]. As a foundational
experiment in the liver field, Waxman et al. [43–46] observed
that the conditional liver-specific deletion of the STAT5a/b
locus in the mouse using the albumin-Cre and loxP
approach led to the abrogation of sex-biased gene expression
in the liver.
We studied STAT5a/b in vascular cells in terms of its
contribution to the sex-bias phenotype in PAH induced in
mice following chronic hypoxia [19–21]. We generated
mice with heterozygous or homozygous conditional dele-
tions of the STAT5a/b locus in vascular smooth muscle cells
(SMCs). Although, Wt males subjected to hypoxic stress
showed significant pulmonary arterial and cardiac remodel-
ing, with Wt females showing minimal changes (a male-
dominant phenotype), the SMC-specific STAT5 −/− mice
hypoxic females showed the severest manifestations of PA
remodeling (a female-dominant phenotype) [19]. The
reversal of sex bias in this model of PAH did not require
the complete loss of STAT5a/b genes. Even heterozygous
conditional STAT5a/b+/− mice (thus, with a 50% loss of
STAT5a/b) showed a loss of the male-dominant PAH phe-
notype [19]. The observation in the present study that these
SMC:STAT5a/b−/− mice also showed reduced expression of
BCL6 in the tunica media/SMCs in pulmonary arterial seg-
ments in both normoxic and hypoxic mice irrespective of
sex (Figure 3) was consistent with the known role of STAT5
as a transcription factor activating BCL6 gene expression
(Figure 1) [47–51]. In as much as it is known that BCL6
is a broad-spectrum transcriptional repressor [49–52], the
reduced expression of BCL6 in SMC:STAT5a/b−/− mice
prompted us to test the involvement of BCL6 per se in
the sex bias observed in this model of PAH by genetically
deleting BCL6 in SMCs in mice. Since it has already been
shown that mice with whole-body knockout of the transcrip-
tional repressor BCL6 showed increased production of
proinflammatory cytokines (IL-6, IFN-gamma, and IL-4),
developed generalized vasculitis including pulmonary vascu-
litis, grew poorly, and lived only 6–8 weeks [52], in the
present study we specifically investigated the effects of
tissue-specific BCL6 deletion only in vascular SMCs.
We discovered that SMC-specific deletion of BCL6 led
to an abrogation of the male-dominant sex bias seen in
hypoxic Wt mice. The data provide evidence for the
involvement of the BCL6 axis in the sex bias observed in
the chronic hypoxia-induced model of PAH in mice. This
represents a successful test of the neuroendocrine-STAT5
hypothesis of sex bias in hypoxic PAH in mice in terms
of the involvement of a predicted downstream player—the
involvement of BCL6.
In preliminary experiments, we have initiated tests of the
involvement of the predicted upstream participant—the
pituitary—in sex bias in hypoxic PAH in mice (Figure 1).
Preliminary data suggest that hypophysectomy also abro-
gates the sex bias observed in Wt mice (data not shown).
We have previously reported that a marked decrease in
STAT5a/b and BCL6 was observed in SMCs in obliterative
lesions in human IPAH—in women and men [19, 21]. These
observations suggested a role of aberrations in the STAT5-
BCL6 axis in the pathogenesis of the human disease. It is long
established that 30–50% of patients with acromegaly develop
systemic hypertension [58–60]. Although respiratory compli-
cations in acromegaly are known to include sleep-breathing
disorders and “respiratory insufficiency” [60], there is little
information about the pulmonary arterial circulation per se
in such patients. Whether patients with IPAH have altered
GH secretion kinetics could be evaluated using patterns of
exercise-induced GH secretion [61–63].
5. Conclusions
The present study represents a successful test of one
downstream element—BCL6—in the neuroendocrine-GH-
STAT5-BCL6 sex-bias hypothesis in an experimental model
of PAH. The insights obtained are likely to apply to sex bias
in other vascular disease models and the human disease
[20, 21]. While the present study has focused on the neuro-
endocrine pathway that indirectly mediates the feminizing
effect of estrogens, we realize that there are extensive studies
that highlight the direct effects of estrogens in vascular tissues
[6, 7, 9–18]. From our perspective, the development of sexual
dimorphism in vascular disease likely includes both upstream
indirect effects initiated by sex hormones at the hypothalamus
and mediated through the GH-STAT5-BCL6 pathway
[19–21] as well as direct effects of sex hormones on vascular
cells [6, 7, 9–18].
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